乙酰脱氢酶1在乳腺癌前哨淋巴结中的表达及临床意义

doi:10.3969/j.issn.1009-976X.2023.01.004

摘要/Abstract

摘要： 目的探讨乙醛脱氢酶1（ALDH1）在乳腺癌前哨淋巴结中的表达及其临床意义。方法收集2021年05月至2022年05月在茂名市人民医院行乳腺癌手术患者的临床资料,釆用免疫组织化学染色法检测乳腺癌转移的前哨淋巴结（n=26）和未转移的前哨淋巴结（n=29）中ALDH1的表达情况,分析前哨淋巴结中 ALDH1 的表达情况与原发灶临床病理特征及预后指标之间的关系。结果乳腺癌转移前哨淋巴结和未转移前哨淋巴结中 ALDH1 阳性表达率分别为76.9%（20/26）、17.2%（5/29）,转移前哨淋巴结中 ALDH1 阳性表达率显著高于未转移前哨淋巴结（P< 0.01）。将乳腺癌前哨淋巴结中 ALDH1 的表达情况与原发灶的组织学分级、临床分期、肿瘤直径、雌激素受体、孕激素受体、人类表皮生长因子受体2、Ki-67的表达情况及分子分型进行差异性分析,显示均无统计学意义（P>0.05）,但与患者的年龄有关（P<0.05）;将ALDH1的表达情况与腋窝淋巴结转移情况以及与术后病理明确性质的前哨淋巴结的准确性进行差异性分析,显示具有统计学意义（P<0.01）。结论乳腺癌前哨淋巴结中 ALDH1 表达情况与肿瘤临床分期、肿瘤直径、组织学分级、ER、PR、HER-2、Ki-67、分子分型等预后指标无关,与患者年龄、腋窝区域淋巴结转移情况及术后病理前哨淋巴结的良恶性有关。

关键词: 乳腺癌, 乙醛脱氢酶1, 前哨淋巴结

Abstract: Objective To investigate the expression of aldehyde dehydrogenase 1 （ALDH1） in sentinel lymph nodes of breast cancer and its clinical significance. Methods The clinical data of patients who underwent breast cancer surgery in Maoming People′s Hospital between May 2021 and May 2022 were collected. The expression of ALDH1 in sentinel lymph nodes with metastasis （n = 26） and without metastasis n = 29） of breast cancer was detected by immunohistochemical staining. Results The positive expression rate of ALDH1 in breast cancer metastatic sentinel lymph nodes and non metastatic sentinel lymph nodes was 76.9% （20/26） and 17.2% （5/29）, respectively. The positive expression rate of ALDH1 in metastatic sentinel lymph nodes was significantly higher than that in non metastatic sentinel lymph nodes （P<0.01）. It was found that there was no statistical significance between the expression of ALDH1 in sentinel lymph nodes with histological grading, clinical stage, tumor diameter, expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and molecular types （P>0.05）, but it was related to patient′s age （P<0.05）, the difference between the expression of ALDH1 and axillary lymph node metastasis, as well as the accuracy of sentinel lymph nodes with clear pathological characteristics after surgery, was statistically significant （P<0.01）. Conclusion The expression of ALDH1 in sentinel lymph nodes of breast cancer is not related to clinical stage, tumor diameter, histological grade, ER, PR, HER-2, Ki-67 and molecular types, but related to the patient′s age, axillary lymph node metastasis and postoperative pathological state of sentinel lymph node.

Key words: breast cancer, ALDH1, sentinel lymph node

中图分类号:

R739.7

申美莹, 潘华文, 赵丽, 胡波涛, 徐波, 韦伟, 崔军威. 乙酰脱氢酶1在乳腺癌前哨淋巴结中的表达及临床意义[J]. 岭南现代临床外科, 2023, 23(01): 19-25.

SHEN Mei-ying, PAN Hua-wen, ZHAO Li, HU Bo-tao, XU Bo, WEI Wei, CUI Jun-wei. The expression and clinical significance of aldehyde dehydrogenase 1 in sentinel lymph nodes of breast cancer[J]. Lingnan Modern Clinics In Surgery, 2023, 23(01): 19-25.

参考文献

[1] Miller KD, Nogueira L, Devasia T, et al.Cancer treatment and survivorship statistics, 2022[J]. CA Cancer J Clin, 2022, 72(5): 409-436.
[2] Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci USA, 2003, 100(7): 3983-3988.
[3] Luo M, Clouthier SG, Deol Y, et al.Breast cancer stem cells: current advances and clinical implications[J]. Methods Mol Biol, 2015, 1293: 1-49.
[4] Yang F, Xu J, Tang L, et al.Breast cancer stem cell: the roles and therapeutic implications[J]. Cell Mol Life Sci, 2017, 74(6): 951-966.
[5] Lin CY, Barry-Holson KQ, Allison KH.Breast cancer stem cells: are we ready to go from bench to bedside?[J]. Histopathology, 2016, 68(1): 119-137.
[6] Marcato P, Dean CA, Giacomantonio CA, et al.Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform[J]. Cell Cycle, 2011, 10(9): 1378-1384.
[7] Marcato P, Dean CA, Pan D, et al.Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis[J]. Stem Cells, 2011, 29(1): 32-45.
[8] Huang EH, Hynes MJ, Zhang T, et al.Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis[J]. Cancer Res, 2009, 69(8): 3382-3389.
[9] Ginestier C, Korkaya H, Dontu G, et al.La cellule souche cancéreuse: un pilote aux commandes du cancer du sein [The cancer stem cell: the breast cancer driver][J]. Med Sci (Paris), 2007, 23(12): 1133-1139.
[10] Deng S, Yang X, Lassus H, et al.Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers[J]. PLoS One, 2010, 5(4): e10277.
[11] Ginestier C, Hur MH, Charafe-Jauffret E, et al.ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome[J]. Cell Stem Cell, 2007, 1(5): 555-567.
[12] Tanaka K, Tomita H, Hisamatsu K, et al.ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma[J]. Oncotarget, 2015, 6(28): 24722-24732.
[13] Li X, Wan L, Geng J, et al.Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome[J]. J Thorac Oncol, 2012, 7(8): 1235-1245.
[14] Yang L, Ren Y, Yu X, et al.ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma[J]. Mod Pathol, 2014, 27(5): 775-783.
[15] Tomita H, Tanaka K, Tanaka T, et al.Aldehyde dehydrogenase 1A1 in stem cells and cancer[J]. Oncotarget, 2016, 7(10): 11018-11032.
[16] Balicki D.Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1[J]. Cell Stem Cell, 2007, 1(5): 485-487.
[17] Morimoto K, Kim SJ, Tanei T, et al.Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression[J]. Cancer Sci, 2009, 100(6): 1062-1068.
[18] Eser M, Kement M, Kaptanoglu L, et al.A prospective comparative study to assess the contribution of radioisotope tracer method to dye-only method in the detection of sentinel lymph node in breast cancer[J]. BMC Surg, 2013, 13: 13.
[19] Alix-Panabières C, Pantel K.Challenges in circulating tumour cell research[J]. Nat Rev Cancer, 2014, 14(9): 623-631.
[20] Bidard FC, Peeters DJ, Fehm T, et al.Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data[J]. Lancet Oncol, 2014, 15(4): 406-414.
[21] Baccelli I, Schneeweiss A, Riethdorf S, et al.Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay[J]. Nat Biotechnol, 2013, 31(6): 539-544.
[22] Barriere G, Riouallon A, Renaudie J, et al.Mesenchymal characterization: alternative to simple CTC detection in two clinical trials[J]. Anticancer Res, 2012, 32(8): 3363-3369.
[23] El Nemr Esmail RS, El Farouk Abdel-Salam LO, Abd El Ellah MM. Could the Breast Prognostic Biomarker Status Change During Disease Progression? An Immunohistochemical Comparison between Primary Tumors and Synchronous Nodal Metastasis[J]. Asian Pac J Cancer Prev, 2015, 16(10): 4317-4321.
[24] Idirisinghe PK, Thike AA, Cheok PY, et al.Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance[J]. Am J Clin Pathol, 2010, 133(3): 416-429.
[25] Takeuchi S, Baghdadi M, Tsuchikawa T, et al.Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer[J]. Cancer Res, 2015, 75(13): 2629-2640.
[26] Fleissig A, Fallowfield LJ, Langridge CI, et al.Post-operative arm morbidity and quality of life. Results of the ALMANAC randomized trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer[J]. Breast Cancer Res Treat, 2006, 95(3): 279-293.
[27] 陈鹏, 王永胜. 前哨淋巴结活检的最新进展[J/CD]. 中华普外科手术学杂志:电子版, 2011, 5(4): 444-448.
[28] 申美莹. ALDH1在乳腺癌前哨淋巴结中表达的临床价值研究 [D]. 汕头大学, 2015.